Sakata Y, Munakata A, Baba T, Saitoh S, Itoh T, Tamura Y, Furukohori N, Suzuki H, Kimura T, Kawata K
Gan To Kagaku Ryoho. 1988 Jul;15(7):2065-71.
Our cooperative study group carried out a controlled study of MQF-OK therapy with tegafur (FT) (group A) and with UFT (group B), a compound of FT and uracil in the molar ratio of 1:4, on various advanced gastrointestinal cancers. From January 1985 to May 1987, 91 patients were entered into this study, and 11 cases were ineligible for the protocol (11%). Fifty of 80 cases had advanced gastric cancer, 30 had pancreatic cancer or other cancers, such as colon cancer, and biliary tract cancer. They were divided into group A or B at random. There was no difference in the patient characteristics between group A and B. In gastric cancer, 23 of 50 cases were randomized into group A and 27 cases into group B. Two cases in group A (8.7%) and 7 cases in group B (25.9%) showed PR. The response rate of group B was better than that of group A, but the value of P by Kruskal-Wallis test was 0.27. Thirteen of the 30 other cancers were randomized into group A and 17 cases into group B. Three cases in group A and B, respectively, showed PR. There was no significant difference between the two groups in terms of antitumor effect, prolongation of life or side effects. In conclusion, it was suggested that the MQF-OK therapy with UFT was beneficial for the Remission Induction Therapy in advanced gastric cancer.
我们的合作研究小组对替加氟（FT）（A组）和优福定（UFT，FT与尿嘧啶摩尔比为1:4的化合物）（B组）用于各种晚期胃肠道癌的MQF-OK疗法进行了对照研究。1985年1月至1987年5月，91例患者进入本研究，11例不符合方案要求（11%）。80例患者中，50例患有晚期胃癌，30例患有胰腺癌或其他癌症，如结肠癌和胆管癌。他们被随机分为A组或B组。A组和B组患者的特征没有差异。在胃癌患者中，50例中有23例随机分为A组，27例分为B组。A组2例（8.7%）和B组7例（25.9%）显示部分缓解（PR）。B组的缓解率优于A组，但经Kruskal-Wallis检验，P值为0.27。其他30例癌症中，13例随机分为A组，17例分为B组。A组和B组分别有3例显示PR。两组在抗肿瘤效果、生存期延长或副作用方面没有显著差异。总之，提示优福定的MQF-OK疗法对晚期胃癌的诱导缓解治疗有益。
